Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors

Nuclear Medicine and Biology

Volumn 34, Issue 6, 2007, Pages 651-657

  Gandomkar, Mostafa ^a   Najafi, Reza ^a   Shafiei, Mohammad ^a   Mazidi, Mohammad ^a   Ebrahimi, Sayed Esmaeil Sadat ^b  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

99mTc; HYNIC; Internalization; Octreotide; Somatostatin receptor; Tumor

Indexed keywords

ETHYLENEDIAMINE DERIVATIVE; N,N' ETHYLENEDIAMINEDIACETIC ACID; OCTREOTIDE 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID 8 THREONINE TC 99M; PEPTIDE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TRICINE; UNCLASSIFIED DRUG; (TECHNETIUM 99M EDDA TRICINE HYNIC(0) NAL(1) THR(8))OCTREOTIDE; (TECHNETIUM 99M-EDDA-TRICINE-HYNIC(0)-NAL(1)-THR(8))OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; OCTREOTIDE; SOMATOSTATIN; SSTR2 PROTEIN, MOUSE; TECHNETIUM COMPLEX;

AFFINITY LABELING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNALIZATION; ISOTOPE LABELING; LIGAND BINDING; MALE; NONHUMAN; RADIATION DETECTION; RADIOCHEMISTRY; RAT; ANIMAL; CELL CULTURE; CELL MEMBRANE; CHEMISTRY; EXPERIMENTAL NEOPLASM; LEWIS RAT; METABOLISM; MOUSE; NEOPLASM; QUALITY CONTROL; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CELL MEMBRANE; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; INDICATORS AND REAGENTS; MALE; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; QUALITY CONTROL; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 34547839755     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.06.006     Document Type: Article

References (23)

1. Weiner R.E., and Thakur M.L. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57 (2002) 749-763
2. Behr T.M., Behe M., and Beeker W. Diagnostic application of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 43 (1999) 268-280
3. Ginj M., and Maecke H.R. Radiometallo-labeled peptides in tumor diagnosis and therapy. In: Sigel A., and Sigel H. (Eds). Metal ions in biological systems (2004), Marcel Dekker Inc., New York (NY) 109-142
4. 111In-octreotide. J Nucl Med 41 (2000) 1114-1119
5. 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl Med Biol 22 (1995) 25-30
6. Reubi J.C., Waser B., Schaer J.C., and Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28 (2001) 836-846
7. Reubi J.C., Laissue J.A., Krenning E., and Lamberts S.W. Somatostatin receptor sst1-sst5 expression in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43 (1992) 27-35
8. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
9. Ferone D., van Hagen M.P., Kwekkeboom D.J., van Koetsveld P.M., Mooy D.M., Lichtenauer-Kaligis E., et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 85 (2000) 1719-1726
10. Papotti M., Croce S., Bello M., Bongiovanni M., Allia E., Schindler M., et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 439 (2001) 787-797
11. Reubi J.C., and Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30 (2003) 781-793
12. 1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 41 (2000) 636-642
13. Halmos G., Sun B., Schally A.V., Hebert F., and Nagy A. Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab 85 (2000) 3509-3512
14. 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 44 (2003) 708-716
15. Ginj M., Chen J., Walter M.A., Eltschinger V., Reubi J.C., and Maecke H.R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11 (2005) 1136-1145
16. Abrams M.J., Juweid M., tenKate C.I., Schwartz D.A., Hauser M.M., Gaul F.E., et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31 (1990) 2022-2028
17. Froidevaux S., Heppeler A., Eberle A.N., Meier A.M., Häusler M., Beglinger C., et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 141 (2000) 3304-3312
18. 3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 29 (2002) 742-753
19. Wild D., Schmitt J.S., Ginj M., Maecke H.R., Bernard B.F., Krenning E., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30 (2003) 1338-1347
20. Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 47 (2001) 40-53
21. Froidevaux S., Hintermann E., Torok M., Maecke H.R., Beglinger C., and Eberle A.N. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 59 (1999) 3652-3657
22. Duncan J.R., Stephenson M.T., Wu H.P., and Anderson C.J. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 57 (1997) 659-671
23. Raulf F., Pérez J., Joyer D., and Bruns C. Differential expression of five somatostatin receptor subtypes, sstr1-5, in the CNS and peripheral tissue. Digestion 55 Suppl 3 (1994) 46-53